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Background: Cervical screening is currently recommended every two years in sexually active women aged 18-20
to 69 years in Australia. Direct replacement of conventional cytology with liquid-based cytology (LBC) for cervical
screening was rejected for public funding on grounds of cost-effectiveness, first in 2002 and again in 2009, but LBC
is performed as an adjunct to conventional cytology in women who elect to pay. The objective of this study was to
describe prevalence and predictors of use of LBC in Australia’s most populous state, New South Wales (NSW).
Methods: We performed cross-sectional and population-based cohort analyses using data from the state Pap Test
Register in NSW. We calculated the age-adjusted proportion of women aged 20-69 years electing to have
adjunctive LBC over the period from 2006-2010. We also calculated the fully-adjusted odds ratios for the association
between subsequent LBC use and age, socioeconomic status, place of residence, previous cytological history and
provider type in a cohort of 360,247 women who had an index cervical cytology test in 2006–8.
Results: Uptake of LBC varied between 29.7% (95% Confidence Interval (CI): 29.5-30.0%) in 2006/7 and 26.6%
(95% CI: 26.4-26.9%) in 2009/10. LBC was more likely to be used in women aged 30-44 years, if it had been used
previously (OR13.58, 95% CI: 13.33-13.84), if the previous test result was abnormal (OR2.62, 95% CI:2.53-2.72) or
unsatisfactory (OR2.37, 95% CI:2.27-3.47), or if a gynaecologist requested the test (OR1.50, 95% CI:1.46-1.54). Uptake
was least for women in remote/very remote areas (OR0.68; 95% CI:0.57-0.80 referenced to those in major cities)
and in lower socioeconomic groups (OR 0.41, 95% CI:0.40-0.42 for lowest versus highest SES quintile).
Conclusion: In the current environment in NSW, Australia, in which public funding for LBC has not been available,
adjunctive uptake of LBC depends strongly on a woman’s age, her screening history and socioeconomic factors.
These findings provide important context for a current review of technologies used in the National Cervical
Screening Program in Australia.
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The National Cervical Screening Program in Australia
currently recommends that women are screened every
2 years between 18–20 and 69 years using conventional
cytology [1]. However, organised cervical screening pro-
grams in several other countries, including England,
Scotland and New Zealand, have replaced conventional
cytology with liquid-based cytology (LBC), which is also
now used for most cervical cytology tests in the USA.
LBC is associated with fewer technically unsatisfactory
tests, and hence fewer repeat tests, than conventional
cytology, and this has been one of the underlying drivers
of its cost-effectiveness in some settings, such as
England, in which the unsatisfactory rate associated with
conventional cytology was high (>7.5%) [2]. However,
systematic reviews have found that manually-read LBC
has close to equivalent sensitivity, but somewhat lower
specificity, than conventional cytology for detection of
biopsy-confirmed high grade precancerous cervical
intraepithelial neoplasia (CIN2+) [3,4]. The evidence on
the relative performance of image-read LBC (in which an
automated computer imaging system is used to assist in
slide reading) is much more limited, but two Australian
studies have provided evidence to suggest that one of the
available systems has an increased rate of detection of
CIN2+ compared to conventional cytology [5,6]. The
clarity of microscopic interpretation, improvements in
laboratory processing, and potential for performing
additional tests on the sample, including testing for the
human papillomavirus (HPV), probably underpins the
popularity of LBC with clinicians and pathologists [7]. In
general terms, the ability to perform HPV DNA testing
from the LBC sample is of increasing importance as HPV
testing is considered for incorporation into screening
programs, for example as a triage test for low grade
cytological results. HPV DNA triage testing in conjunc-
tion with LBC screening is now used, for example, in
England and New Zealand, and several other countries.
LBC has been evaluated by Australia’s Medical
Services Advisory Committee (MSAC) as a direct
replacement to conventional cytology on two previous
occasions, and on both of these was rejected for public
funding. A 2002 review concluded “there is currently
insufficient evidence pertaining to liquid based cytology
for cervical screening” [8], whereas a second review in
2009, which separately considered manually and image-
read LBC, led MSAC to conclude that, “in comparison
to the Papanicolaou (Pap) test, LBC is safe, is at least as
effective, but is not cost effective at the price requested”
[4], The cost-effectiveness finding was made in context
of favourable assumptions about the relative sensitivity
of LBC and was related, in part, to the low unsatisfactory
rate currently experienced with conventional cytology in
Australia (~2.2%) [4,9], and to the shorter recommendedscreening interval compared to that in other countries
[4,10]. Currently, LBC is available as an adjunctive test if
women elect to pay, with the price varying according to
laboratory (up to ~ $40-$60). Adjunctive testing is
performed using the split-sample technique, in which a
conventional cytology slide is prepared with residual
sample collected in a vial. The results are reported in an
integrated fashion, so that an abnormality seen in either
test determines the final result.
The National Cervical Screening Program in Australia
has announced the Renewal of the National Cervical
Screening Program. The aim is to “review the science
and technologies related to the program to ensure
that all Australian women have access to a cervical
screening program that is based on the best available
evidence and promotes best clinical practice” [11]. A
new evaluation of LBC will be considered as part of
this process. In this context, the aim of the current
study was to provide accurate data on prevalence of
adjunctive LBC use, and the important factors influ-
encing use.
Methods
We obtained unit record data from the population-
based NSW Pap Test Register (PTR) [12] for all women
20–69 years of age who had cervical cytology performed
in NSW in fiscal years (FY) 2006/7 to 2009/10. The PTR
holds and links individual test records for each identifi-
able woman. All pathology laboratories in NSW have
provided details to the PTR of cervical cytology or path-
ology tests performed since 1996. Since 2006, cervical
cytology tests have been classified as having been read
from conventional cytology alone or from conventional
cytology with adjunctive LBC. A very small proportion
of tests (0.23%) were reported as using LBC alone, and
these were excluded from the current analysis. A small
proportion of women (0.8%) choose not to have identifi-
able records kept by the PTR [13], and these were also
excluded from the analysis, because test records from
these women could not be linked to each other to obtain
longitudinal information.
To assess the prevalence of LBC uptake, we used the
first cervical cytology test for each woman who had
cytology in each quarter, and calculated the age-standar-
dised proportions of these tests for which adjunctive LBC
was used, using the Australian 2001 standard population.
We used linear regression to examine trends in LBC
uptake over the period of interest. Because it is possible
that women with a prior abnormality might be more likely
to elect to have adjunctive LBC testing, we also assessed
prevalence of use according to whether or not the woman
had a prior abnormal cytology or histology test, including
cytological predictions of possible low grade squamous
intraepithelial lesions (pLSIL; broadly equivalent to
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cytological classification) in the past 5 years. We did not
include in the analysis a small number of tests (3.8%) that
were preceded in the previous 5 years by a test with an
unsatisfactory result and an otherwise normal test history.
To examine predictors of LBC use, we identified a
cohort of women aged 20–67 years (and who were thus
in the age group recommended for screening for at least
two subsequent years) who had a cervical cytology test
(the index test) in the period 1 July 2006 to 30 March
2008, and who had at least one subsequent test within
27 months (the period of 27 months was chosen since in
NSW if a woman does not attend for screening at the 2-
yearly recommended interval, a reminder letter is sent
by the register at 27 months after her last screening
test). We excluded any women with a history of cyto-
logical or histological abnormalities or an unsatisfactory
result in the 5 years before the index test. Logistic
regression was used to calculate odds ratios (ORs) for
use of LBC in the subsequent test, adjusted for age and
then fully adjusted for all other potential predictors of
LBC use in the analysis. The potential predictors
included the type of index test (conventional cytology or
adjunctive LBC), the index test result (normal, abnormal
or unsatisfactory), the type of provider, allocated with
reference to discipline code (general practitioner, gynae-
cologist or other/unknown provider), area of residence
(major city, inner regional area, outer regional area,
remote/very remote) [14] and socioeconomic status
(in quintiles of the index of relative socioeconomic
disadvantage based on characteristics of the local
government area of residence as ascertained at the































Figure 1 Adjunctive LBC uptake in NSW women,* according to screen
cervical cytology test for each woman who had cytology in each quarter, a
which adjunctive LBC was used, using the Australian 2001 standard populaHuman research ethics committee approval for the
study was obtained from the NSW Population and
Health Services Human Research Ethics Committee. All
authors had full access to the de-identified dataset
used for analysis (including interim statistical reports
and tables).
Results
Prevalence of adjunctive LBC use
Figure 1 shows the age-adjusted percentage uptake of
adjunctive LBC over the 4 year period from FY2006/7 to
FY2009/10, and Additional file 1: Table S1 shows the
numbers of women being screened per quarter and the
proportion choosing to have LBC. Uptake fell slightly
from 29.7% (95% confidence interval (CI) 29.5%-30.0%)
in the third quarter (Q3) of 2006 to 26.6% (95% CI
26.4%-26.9%) in Q2 of 2010 (test for trend in decline;
p < 0.001). In women with entirely normal cervical
cytology in the preceding 5 years, LBC uptake fell
slightly from 28% (95% CI27.7%-28.3%) in Q3 of 2006
to 25.3% (95% CI:25.0%-25.5%) in Q2 of 2010 (test
for trend in decline; p < 0.001). In women with one or
more abnormal cervical cytology results in the preceding
five years, LBC uptake remained stable over the period:
44.7% (95% CI:43.9%-45.4%) in Q3 of 2006 and 44.0%
(95% CI:43.1%-44.9%) in Q2 of 2010.
Predictors of adjunctive LBC use
In women who had neither an abnormal nor an unsa-
tisfactory cytology test in the 5 years before their index
cytology test, age, place of residence and socioeconomic
status were each independent and significant predictors
of adjunctive LBC use in the subsequent test (Table 1).Any history
Normal history
Abnormal history
ing history in previous 5 years: FY2006-2010. *Using the first
nd calculating the age-standardised proportions of these tests for
tion (see text for more detail).
Table 1 Odds ratios for predictors of adjunctive LBC uptake in NSW
Number of women LBC use % Age-adjusted OR 95% CI Fully adjusted OR* 95% CI
Age (years)
20-24 19,099 27.8 0.74 0.71-0.77 0.82 0.78-0.86
25-29 30,062 31.4 0.88 0.85-0.91 0.92 0.89-0.96
30-34 42,628 34.1 0.99 0.97-1.02 0.98 0.95-1.02
35-39 49,313 34.2 1 - 1 -
40-44 49,019 33.8 0.98 0.95-1.01 1.02 0.99-1.05
45-49 49,318 31.5 0.88 0.86-0.91 0.94 0.91-0.97
50-54 43,109 29.6 0.81 0.79-0.83 0.90 0.86-0.93
55-59 38,589 27.8 0.74 0.72-0.76 0.84 0.81-0.87
60+ 38,336 25.2 0.65 0.63-0.67 0.79 0.76-0.82
P-value‡ <0.001 <0.001
Area of residence
Major city 196,046 37.2 1 - 1 -
Inner regional 121,486 26.6 0.62 0.61-0.63 0.83 0.81-0.85
Outer regional 38,702 14.3 0.29 0.28-0.30 0.66 0.63-0.68
Remote or very remote 2,362 11.6 0.22 0.20-0.25 0.68 0.57-0.80
P-value‡ <0.001 <0.001
Socioeconomic status
1st quintile (highest) 96,000 50.3 1 - 1 -
2nd quintile 68,520 35.4 0.54 0.53-0.55 0.68 0.66-0.70
3rd quintile 71,798 20.5 0.26 0.25-0.26 0.44 0.43-0.46
4th quintile 61,803 20.9 0.26 0.26-0.27 0.45 0.43-0.46
5th quintile (lowest) 60,475 17.9 0.22 0.21-0.22 0.41 0.40-0.42
P-value for trend‡‡ <0.001 <0.001
Use of adjunctive LBC in index cytology
Conventional cytology only 249,037 13.9 1 - 1 -
Adjunctive LBC 106,819 70.9 15.13 14.87-15.40 13.58 13.33-13.84
P-value‡ <0.001 <0.001
Result of index cervical cytology
Normal 324,432 29.8 1 - 1 -
Abnormal 21,009 49.9 2.42 2.35-2.49 2.62 2.53-2.72
Unsatisfactory 13,996 30.3 1.03 0.99-1.06 2.37 2.27-2.47
P-value‡ <0.001 <0.001
Provider type for subsequent cytology
General practitioners 293,325 29.3 1 - 1 -
Gynaecologists 49,327 44.6 1.91 1.89-1.95 1.50 1.46-1.54
Other and unknown 2,764 21.0 0.65 0.59-0.71 0.73 0.65-0.82
P-value‡ <0.001 <0.001
*OR adjusted for age, index smear cytology result, index smear type of test (conventional cytology or conventional cytology with adjunctive LBC), SES, provider
type, and area of residence.
‡ Obtained from global multivariable model.
‡‡Obtained from global multivariable model with test for trend performed.
Predictors of adjunctive uptake in a cohort of 360,247 women aged 20-67 years, attending for cervical screening for an index cervical cytology in the period
1 July 2006 to 30 March 2008.
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at 30–44 years then fell again. Relative to an OR of 1 at
35–39 years of age, an estimated 20% reduction in the
odds of having adjunctive LBC was observed in women
aged 20–24 years and 60+ years of age. Adjunctive use
of LBC for the index cervical cytology was by far the
strongest predictor of LBC use in a subsequent cervical
cytology test; when LBC was used in the index cytology,
the odds of using LBC in the subsequent test were
increased by more than 13 times, even after adjusting
for all other factors (OR 13.6, 95% CI:13.3-13.8). An
abnormal result or an unsatisfactory result in the index
cytology test also strongly predicted LBC use in the sub-
sequent test, more than doubling the odds of using LBC
in the subsequent test (OR 2.62, 95% CI:2.53-2.72) for
abnormal and OR 2.37, 95% CI:2.27-3.47 for unsatisfac-
tory tests, respectively). Gynaecologists were more likely
than GPs and other providers to request LBC (OR 1.50,
95% CI:1.46-1.54), even after taking into account other
factors. Uptake was highest in women in major cities
and of highest socioeconomic status (reference ORs of
1) and least for women in remote/very remote areas
(OR0.68, 95% CI:0.57-0.80) or in the lowest SES quintile
(OR 0.41, 95% CI: 0.40-0.42).
We also assessed evidence for interaction between
the variables by including terms for multiplicative
interaction in the fully adjusted regression models.
We identified some evidence for interaction between
socioeconomic status and age in predicting LBC up-
take. Therefore, in order to more fully describe LBC
uptake in relation to these variables we performed
more detailed analysis as follows: (1) We created a
compound variable based on broad categories of age
(<40; 40+ years) and socioeconomic status (highest
three quintiles; lowest two quintiles). Compared to
women <40 years in the higher SES category, the fully
adjusted odds of adjunctive LBC uptake in women of
this age group in the lower SES category were 0.65
(95% CI:0.64-0.67); the odds in women 40+ years in
the higher SES category were 0.98 (CI:0.95-0.98) and
the odds in women in this age group in the lower SES
category were 0.62(CI:0.60-0.63). (2) Using 5-yearly
stratification by age, but constructing separate models,
we found that the odds ratios for LBC uptake for
lower vs. higher SES were 0.63(CI:0.61-0.65) and 0.65
(0.63-0.67) for women <40, 40+ years, respectively;
and the result in each age group by quintiles of SES
were very similar to our main findings for women of
all ages. Results were also similar if broad age classifi-
cations were made according <30,30+ years and
<50,50+ years. Therefore, though the findings were
very similar across both age groups for the effect of
SES, a slight interaction was noted with age such that
the odds of LBC uptake in lower SES women at olderages were slightly higher than for lower SES women
at younger ages.
Discussion
To our knowledge, this is the first study that provides
information on prevalence and predictors of use of liquid-
based cytology (LBC) for cervical screening in an
Australian setting. We used data from a state-based regis-
try in which only a small proportion of women (<1%)
chose not to disclose identifiable information. The study
was also conducted in the context of a relatively high
overall screening participation rate in NSW, in which
58.8% of women aged 20–69 years were screened every
2 years [13] and 71.2% every 3 years in 2007-8 [13]. We
found that adjunctive uptake of LBC in NSW is high, at
approximately 27-30%, but that the decision to use LBC
depends strongly on a woman’s age and previous scree-
ning history, and use of the technology is increased in
high socioeconomic status and urban groups. Therefore,
the study demonstrates that uptake of LBC, to date, has
not been comparable for all groups of women; these findings
are relevant to considerations of equity when new tech-
nologies for cervical screening are made available.
It is notable that the observed pattern of LBC uptake
with age, which peaks in women in their thirties and
forties, to an extent mirrors patterns in overall screening
participation which peaks in women in their thirties,
forties and fifties [9,13]. Screening participation has also
been shown to depend on socioeconomic status and area
of residence [9,13]. Taken together with the current
study, these findings suggest that some of the factors
that influence women to participate in cervical screening
might also be involved in the decision to use LBC. Such
factors could be related to financial issues, access to
screening services, or understanding of the benefits of
cervical screening. We also found that use of LBC was
more likely when the test provider was a specialist
gynaecologist, even in a group of women selected to
have a normal history for 5 years prior to the index test,
and after adjusting for having an abnormal index smear
(which may have prompted the specialist referral). It is
possible that greater awareness about LBC technology
amongst specialist providers is a factor in this finding;
and it is possible that the medical practitioner’s recom-
mendation is a factor in the woman's decision to use
LBC. Overall, our findings appear broadly comparable to
historical findings from the USA where the decision to
use LBC as a direct replacement to cytology might have
involved additional costs to the woman; in that country
it has been found that women with more education or
who were living in metropolitan areas were more likely
to have LBC testing [16,17].
Because cytology registers are configured at the state
level, we were not able to analyse national data in the
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considerable influence on national rates since the
population in NSW comprises approximately one third
of the Australian population. However, our findings for
prevalence of uptake are not likely to be generalisable to
other states – for example, uptake in Victoria in 2011 was
4% overall (personal communication, A/Prof. Marion
Saville), whereas to our knowledge, detailed information
on levels of uptake in other states have not been reported.
Probable differences in the overall levels of LBC uptake
between states probably depend on a range of factors
including availability of the technology through specific
laboratories. Nevertheless, even though absolute rates of
uptake in other states probably differ from that in NSW,
our finding that certain factors seem to predispose women
towards choosing LBC may have broader applicability.
It is important that our findings are set in context of
the scale of the potential benefits to women of having
LBC testing. The test sensitivities for conventional
cytology and manually-read LBC for detection of biopsy-
confirmed CIN2+ lesions are similar [3,4], and there is
no evidence, to our knowledge, to suggest that adjunct-
ive testing per se, improves overall sensitivity. However,
there is some initial evidence from two Australian stud-
ies that image-read LBC may deliver greater benefits in
terms of test sensitivity [5,6]. Although in this study we
were unable to quantify the proportion of adjunctive
tests in NSW involving image analysis of the slide
(because this information is not recorded in the NSW
PTR), it is likely that a very high proportion of tests
since 2008 have involved imaging, because the two labora-
tories processing the largest volumes of cytology slides
now routinely use the technology (personal communica-
tion. Prof. Annabelle Farnsworth).
Modelled analysis has previously predicted that under
favourable assumptions about LBC test accuracy, if
image-read LBC were to be introduced as a direct
replacement to conventional cytology in Australia, 68
additional cervical cancer cases and 19 deaths would be
prevented, but 26 additional treatments for high grade
precancerous lesions would be required for each case
prevented [4]. However, this balance of benefits and
harms also depends on other factors such as the age
range for screening and the screening interval, and is
also likely to change over time due to the effects of HPV
vaccination. The National HPV Vaccination Program,
introduced in 2007, involves routine vaccination of
12–13 years old girls and a catch-up of girls and women
aged 12–26 years which was conducted to 2009; there are
already initial indications of a potentially vaccine-related
drop in biopsy-confirmed CIN2+ rates in Australian
females less than 18 years of age [18]. These changes are
likely to have a rapid effect on the balance of benefits and
harms (and cost-effectiveness) of using LBC technology.The findings of our study are timely. They provide
important context on current patterns of uptake of LBC,
which is an important candidate technology for inclu-
sion in the National Cervical Screening Program. The
scope of the Renewal process also includes evaluation of
HPV DNA testing both as a triage test for women with
low grade cytological abnormalities, and as a primary
screening test. Consideration of LBC as a direct replace-
ment for conventional cytology within the national
program will likely take into account the potential to
perform HPV testing from the LBC sample, as well as
the impact of screening interval and age range on the
balance of benefits and harms associated with a move to
LBC. This integrated evaluation of changes to screening
technology, in context of other aspects of screening,
seems warranted.
Conclusions
In the environment in Australia in which public funding
for LBC has not been available, adjunctive uptake of LBC
depends strongly on a woman’s age, her screening history
and socioeconomic factors. These findings provide im-
portant context for a current review of technologies used
in the National Cervical Screening Program in Australia.
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